Australia markets closed

GS Apr 2021 205.000 put

OPR - OPR Delayed price. Currency in USD
Add to watchlist
0.03000.0000 (0.00%)
As of 9:49AM EDT. Market open.
Full screen
Previous close0.0300
Open0.0400
Bid0.0000
Ask0.0000
Strike205.00
Expiry date2021-04-16
Day's range0.0300 - 0.0400
Contract rangeN/A
Volume2
Open interest183
  • Goldman Sachs Q1 earnings smash expectations on banking boom, record revenue
    Editor's pick
    Yahoo Finance

    Goldman Sachs Q1 earnings smash expectations on banking boom, record revenue

    Goldman is preparing for "a world beyond the pandemic," as its first quarter results set a record.

  • Covid Test Maker Cue Health Taps Morgan Stanley, Goldman for IPO
    Bloomberg

    Covid Test Maker Cue Health Taps Morgan Stanley, Goldman for IPO

    (Bloomberg) -- Covid test maker Cue Health Inc. is planning an initial public offering as soon as this year, according to people with knowledge of the matter.The health-care technology company is working with banks including Morgan Stanley and Goldman Sachs Group Inc. on a listing, said the people, who asked not to be identified discussing information that isn’t yet public.The company’s plans, including the timing of an IPO, could still change.A spokesperson for Cue Health didn’t immediately respond to a request for comment. Representatives for Morgan Stanley and Goldman Sachs declined to comment.Cue Health’s tests were used last year by the National Basketball Association to help limit the spread of the coronavirus among team members who played and lived in a so-called bubble in Florida.The U.S. Department of Health and Human Services in October said it would invest $481 million in the San Diego-based company to boost manufacturing of the tests, which processes results in about 20 minutes. Last month, the tests were given emergency approval by the U.S. Food and Drug Administration for home and over-the-counter use.Venture BackersCue Health, led by co-founder and Chief Executive Officer Ayub Khattak, raised $100 million last June from investors including Madrone Capital Partners, Johnson & Johnson Innovation, Decheng Capital and Foresite Capital. The Information reported in December that the company had discussed raising new funding that could have boosted its valuation above $2 billion.The company’s Covid-19 tests are being used in 10 U.S. states at schools, nursing homes and hospitals, among other places. Cue Health has said it’s also working on at-home influenza testing.Last month, it named John Gallagher, a former Becton Dickinson & Co. executive, as chief financial officer. It also hired ex-Livongo executive Erica Palsis as general counsel.Health-care companies focused on coronavirus testing are increasingly turning to public markets to fund growth.LumiraDx, LuciraLumiraDx Ltd. last week agreed to go public through a merger with a special purpose acquisition company. Lucira Health Inc., which went public in February, saw its stock spike this week after its home-testing kit received FDA approval.Hong Kong-based Prenetics Ltd., whose Covid-19 tests were used by the English Premier League, is also planning an IPO, Nikkei has reported.For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2021 Bloomberg L.P.

  • Most Brits expect to be back in the office by end of summer
    Yahoo Finance UK

    Most Brits expect to be back in the office by end of summer

    Around 57% of Brits believe they will be able to return to their workplaces by September, as lockdown restrictions around the country begin to ease.